Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

168.25 +0.37 (+0.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
How Is The Market Feeling About Natera?
 
Via Benzinga
Exploring NASDAQ:NTRA's high growth characteristics.
NATERA INC (NASDAQ:NTRA) is a candidate for high growth investors. Here's why. 
Via Chartmill
Natera to Report its Third Quarter 2024 Results on November 12, 2024
From Natera, Inc.
Via Business Wire
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings. 
Via Benzinga
Topics ETFs Stocks
Evaluating Natera: Insights From 10 Financial Analysts
 
Via Benzinga
Why the high growth investor may take a look at NATERA INC (NASDAQ:NTRA).
Why the high growth investor may take a look at NATERA INC (NASDAQ:NTRA). 
Via Chartmill
Analyst Scoreboard: 9 Ratings For Natera
 
Via Benzinga
Peering Into Natera's Recent Short Interest
 
Via Benzinga
Natera to Present New Renasight Data at ASN Kidney Week 2024
From Natera, Inc.
Via Business Wire
Blue Skies, New Highs Remain Disciplined And Do Not Chase Extended Ideas
It is Fall clean up time. Sell lagging and sagging companies. 
Via Talk Markets
A Biotech Breakout Will Be Led By Small Caps
It’s hard to focus on biotech stocks right now because there are many distractions. The Fed and the rate cuts, AI and semiconductor stocks and geopolitical turmoil seemingly worse than ever. 
Via Talk Markets
Topics Artificial Intelligence Economy
Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase
From Natera, Inc.
Via Business Wire
Peeling Back The Layers: Exploring Natera Through Analyst Insights
 
Via Benzinga
Forecasting The Future: 6 Analyst Projections For Natera
 
Via Benzinga
Tempus AI Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
A Relative Strength Rating upgrade for Tempus AI shows improving technical performance. 
Via Investor's Business Daily
Topics Artificial Intelligence
Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO
From Natera, Inc.
Via Business Wire
First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival
From Natera, Inc.
Via Business Wire
Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
From Natera, Inc.
Via Business Wire
$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The recent stock market dip provided some discounts. 
Via The Motley Fool
Shopify, Palantir And Uber Are Among Top 10 Large Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
Top 10 best performing large-cap stocks last week: Shopify, Palantir, Axon, Fortinet, Trade Desk, Natera, SharkNinja, Zillow, Aspen Tech, Uber. 
Via Benzinga
NTRA Stock Earnings: Natera Beats EPS, Beats Revenue for Q2 2024
NTRA stock results show that Natera beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Natera Reports Second Quarter 2024 Financial Results
From Natera, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
(NTRA) - Analyzing Natera's Short Interest
 
Via Benzinga
Here's How Much You Would Have Made Owning Natera Stock In The Last 5 Years
 
Via Benzinga
Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Natera, Inc.
Via Business Wire
Natera to Report its Second Quarter 2024 Results on August 8, 2024
From Natera, Inc.
Via Business Wire
New MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell Carcinoma
From Natera, Inc.
Via Business Wire
The 3 Best Gene Editing Stocks to Buy in July 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.